Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this prospective cohort study, male pattern baldness was identified as an independent predictor of prostate cancer, while the 2D:4D finger ratio was not associated with the cancer risk.

CEC levels may be a useful marker for predicting prostate cancer progression.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Serum triglyceride levels are not linked to prostate cancer risk.

This study demonstrates that a new Adaptive Modulation and Coding method can improve control performance in Communication-Based Train Control systems using WLAN by reducing average delay through effective transmission mode selection.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Teaching men with simple bladder problems self-management skills can improve their symptoms and quality of life.

This case report describes a patient with systemic sclerosis and severe alopecia areata who experienced complete resolution of hair loss within four months after treatment with topical steroids, minoxidil, and mycophenolate mofetil.

Gene variation affects prostate issues and hair loss.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This review discusses the roles of androgens and androgen receptors in skin-related disorders and suggests that targeting androgen receptors may be a more effective treatment strategy.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study suggests that silver nanoparticles synthesized using Grewia optiva leaf extract exhibit stronger antibacterial and antioxidant properties than the leaf extract alone.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.